A Phase 3 interventional study of Placebo (for alirocumab) and Alirocumab in Hypercholesterolemia, sponsored by Sanofi. Completed at 320 sites in 27 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-12-22.
Sponsored by Sanofi · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies testing alirocumab in Hypercholesterolemia — 1 open to participants now, 2 under way, none of them phase 3. alirocumab · Hypercholesterolemia.
Among the 43 studies testing alirocumab in Hypercholesterolemia, this one has the largest enrollment, is one of 12 that started in 2012, is one of 20 in phase 3, and was the 9th registered.
1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.
Browse Hypercholesterolemia studies →1 of the 43 studies testing alirocumab in Hypercholesterolemia is open now, in 1 country. Recruiting first, the newest first:
University Medical Centre Ljubljana · Sites in Slovenia
Ages 18+
By country, each count listing its studies:
alirocumab: first FDA approval 2015 (PRALUENT), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 12 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 2,341 is above the median of 110 across 976 interventional studies indexed under Hypercholesterolemia.
Median enrollment 107 across the 43 interventional studies. Of the 40 that completed or were terminated, 30 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
39 of 43 have an industry lead sponsor. The 6 most frequent:
Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
38 studies in Hypercholesterolemia by Sanofi: none open now, none under way, none of them phase 3. Of 38 finished, 22 (58%) have results posted.
Among the 38 studies in Hypercholesterolemia by Sanofi, this one has the largest enrollment, is one of 8 that started in 2012, is one of 22 in phase 3, and was the 13th registered.
Sanofi’s Hypercholesterolemia studies by the year they started, since 2007.
2 of the studies testing alirocumab in Hypercholesterolemia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07477704Regeneron PharmaceuticalsA Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia | 2026-12-29 |
| NCT07581808University Medical Centre LjubljanaDual PCSK9 Inhibition With Inclisiran and Alirocumab in Secondary Prevention | 2027-05 |
Add all 2 to your calendar (.ics) → With an account.
Among the 43 studies testing alirocumab in Hypercholesterolemia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Sanofi’s 38 in Hypercholesterolemia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Alirocumab (SAR236553/REGN727) is a fully human monoclonal antibody that binds PCSK9 (proprotein convertase subtilisin/kexin type 9).
Primary Objective of the study:
To evaluate the long-term safety and tolerability of alirocumab in high cardiovascular risk participants with hypercholesterolemia not adequately controlled with their current lipid modifying therapy (LMT).
Secondary Objectives:
The maximum study duration was to be 89 weeks per participant, including a 3-week screening period, a 78-week randomized treatment period and 8-week follow-up period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Either A or B below and who were not adequately controlled with their lipid-modifying therapy:
A) Participants with heterozygous familial hypercholesterolemia (heFH) with or without established coronary heart disease (CHD) or CHD risk equivalents
OR
B) Participants with hypercholesterolemia together with established CHD or CHD risk equivalents.
Exclusion criteria:
The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Placebo (for alirocumab) every 2 weeks (Q2W) added to stable Lipid-Modifying Therapy (LMT) for 78 weeks.
Drug: Placebo (for alirocumab) · Drug: Lipid-Modifying Therapy (LMT)
Alirocumab 150 mg Q2W added to stable LMT for 78 weeks.
Drug: Alirocumab · Drug: Lipid-Modifying Therapy (LMT)
Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with a pre-filled syringe.
Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with a pre-filled syringe.
Also known as: SAR236553, REGN727, Praluent
Statin (rosuvastatin, simvastatin or atorvastatin) at stable dose with or without other LMT as clinically indicated.
Percentage of Participants Who Experienced Adverse Events (AEs)
Reported adverse events are treatment-emergent adverse events that is AEs that developed/worsened during the 'treatment-emergent period' (the time from the first dose of study drug up to the last dose of study drug +70 days).
Time frame: Up to 10 weeks after last study drug administration (maximum of 86 weeks)
Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-Treat (ITT) Analysis
Adjusted least-squares (LS) means and standard errors at Week 24 were obtained from a mixed-effect model with repeated measures (MMRM) to account for missing data. All available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment were used in the model (ITT analysis).
Time frame: From Baseline to Week 52
Percent Change From Baseline in Calculated LDL-C at Week 24 - On-Treatment Analysis
Adjusted LS means and standard errors at Week 24 were obtained from MMRM model including available post-baseline on-treatment data from Week 4 to Week 52 (i.e. up to 21 days after last injection) (on-treatment analysis).
Time frame: From Baseline to Week 52
Percent Change From Baseline in Calculated LDL-C at Week 12 - ITT Analysis
Adjusted LS means and standard errors at Week 12 from MMRM model including available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.
Time frame: From Baseline to Week 52
Percent Change From Baseline in Calculated LDL-C at Week 12 - On-treatment Analysis
Adjusted LS means and standard errors at Week 12 from MMRM model including available post-baseline on-treatment data from Week 4 to Week 52 (i.e. up to 21 days after last injection).
Time frame: From Baseline to Week 52
Percent Change From Baseline in Measured LDL-C at Week 24 - ITT Analysis
Measured LDL-C values via beta quantification method. Adjusted LS means and standard errors at Week 24 from MMRM model including available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.
Time frame: From Baseline to Week 52
Percent Change From Baseline in Apolipoprotein (Apo) B at Week 24 - ITT Analysis
Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.
Time frame: From Baseline to Week 52
Percent Change From Baseline in Apo B at Week 24 - On-Treatment Analysis
Adjusted LS means and standard errors at Week 24 were obtained from MMRM model including available post-baseline on-treatment data from Week 4 to Week 52 (i.e. up to 21 days after last injection).
Time frame: From Baseline to Week 52
Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 24 - ITT Analysis
Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.
Time frame: From Baseline to Week 52
Percent Change From Baseline in Non-HDL-C at Week 24 - On-Treatment Analysis
Adjusted LS means and standard errors at Week 24 from MMRM model including available post-baseline on-treatment data from Week 4 to Week 52 (i.e. up to 21 days after last injection).
Time frame: From Baseline to Week 52
Percent Change From Baseline in Total Cholesterol (Total-C) at Week 24 - ITT Analysis
Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.
Time frame: From Baseline to Week 52
Percent Change From Baseline in Apo B at Week 12 - ITT Analysis
Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.
Time frame: From Baseline to Week 52
Percent Change From Baseline in Non-HDL-C at Week 12 - ITT Analysis
Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.
Time frame: From Baseline to Week 52
Percent Change From Baseline in Total-C at Week 12 - ITT Analysis
Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.
Time frame: From Baseline to Week 52
Percentage of Very High Cardiovascular (CV) Risk Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) or High CV Risk Participants Reaching Calculated LDL-C <100 mg/dL (2.59 mmol/L) at Week 24 - ITT Analysis
Very high CV risk: Heterozygous Familial Hypercholesterolemia (heFH) participants with coronary heart disease (CHD) or CHD risk equivalents or non- Familial Hypercholesterolemia (FH). High CV risk: heFH participants without CHD or CHD risk equivalents. CHD risk equivalent: peripheral arterial disease, ischemic stroke, moderate chronic kidney disease (estimated glomerular filtration rate, 30 to \<60 ml/minute/1.73 m\^2 of body-surface area), or diabetes mellitus plus 2 or more additional risk factors (hypertension; ankle-brachial index of ≤0.90; microalbuminuria, macroalbuminuria, or a urinary dipstick result of \>2+ protein; preproliferative or proliferative retinopathy or laser treatment for retinopathy; or family history of premature CHD). Adjusted percentages at Week 24 were obtained from multiple imputation approach model for handling of missing data. All available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment were included in imputation model.
Time frame: Up to Week 52
Percentage of Very High CV Risk Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) or High CV Risk Participants Reaching Calculated LDL-C <100 mg/dL (2.59 mmol/L) at Week 24 - On-Treatment Analysis
Adjusted percentages at Week 24 were from multiple imputation approach model including available post-baseline on-treatment data from Week 4 to Week 52 (i.e. up to 21 days after last injection).
Time frame: Up to Week 52
Percentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - ITT Analysis
Adjusted percentages at Week 24 were obtained from multiple imputation approach model for handling of missing data. All available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment were included in the imputation model.
Time frame: Up to Week 52
Percentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - On-Treatment Analysis
Adjusted percentages at Week 24 from multiple imputation approach model including available post-baseline data from Week 4 to Week 52 (i.e. up to 21 days after last injection).
Time frame: Up to Week 52
Percent Change From Baseline in Lipoprotein (a) at Week 24 - ITT Analysis
Adjusted means and standard errors at Week 24 were obtained from multiple imputation approach followed by robust regression model for handling of missing data. All available post-baseline data from Week 4 to Week 52 regardless of status on-or off-treatment were included in the imputation model.
Time frame: From Baseline to Week 52
Percent Change From Baseline in HDL-C at Week 24 - ITT Analysis
Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.
Time frame: From Baseline to Week 52
Percent Change From Baseline in Fasting Triglycerides at Week 24 - ITT Analysis
Adjusted means and standard errors at Week 24 from multiple imputation approach followed by robust regression model including all available post-baseline data from Week 4 to Week 52 regardless of status on-or off-treatment.
Time frame: From Baseline to Week 52
Percent Change From Baseline in Apo A1 at Week 24 - ITT Analysis
Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.
Time frame: From Baseline to Week 52
Percent Change From Baseline in Lipoprotein (a) at Week 12 - ITT Analysis
Adjusted means and standard errors at Week 12 from multiple imputation approach followed by robust regression model including all available post-baseline data from Week 4 to Week 52 regardless of status on-or off-treatment.
Time frame: From Baseline to Week 52
Percent Change From Baseline in HDL-C at Week 12 - ITT Analysis
Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.
Time frame: From Baseline to Week 52
Percent Change From Baseline in Fasting Triglycerides at Week 12 - ITT Analysis
Adjusted means and standard errors at Week 12 from multiple imputation approach followed by robust regression model including all available post-baseline data from Week 4 to Week 52 regardless of status on-or off-treatment.
Time frame: From Baseline to Week 52
Percent Change From Baseline in Apo A1 at Week 12 - ITT Analysis
Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.
Time frame: From Baseline to Week 52
Percent Change From Baseline in Calculated LDL-C at Week 52 - ITT Analysis
Adjusted LS means and standard errors at Week 52 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.
Time frame: From Baseline to Week 52
Percent Change From Baseline in Calculated LDL-C at Week 52 - On-Treatment Analysis
Adjusted LS means and standard errors at Week 52 from MMRM model including available post-baseline on-treatment data from Week 4 to Week 52 (i.e. up to 21 days after last injection).
Time frame: From Baseline to Week 52
Percent Change From Baseline in Calculated LDL-C at Week 78 - ITT Analysis
Adjusted LS means and standard errors at Week 78 from MMRM model including all available post-baseline data from Week 4 to Week 78 regardless of status on- or off-treatment.
Time frame: From Baseline to Week 78
Percent Change From Baseline in Calculated LDL-C at Week 78 - On-Treatment Analysis
Adjusted LS means and standard errors at Week 78 from MMRM model including available post-baseline on-treatment data from Week 4 to Week 78 (i.e. up to 21 days after last injection).
Time frame: From Baseline to Week 78
Percentage of Participants Who Experienced Cardiovascular (CV) Events
CV events included coronary heart disease (CHD) death; non-fatal myocardial infarction (MI); fatal and non-fatal ischemic stroke; unstable angina requiring hospitalization; congestive heart failure (CHF) requiring hospitalization; ischemia-driven coronary revascularization procedure. Reported events are CV events as confirmed by an independent Clinical Events Committee (CEC) that occurred during the treatment emergent period ( i.e. from first dose up to the last dose of study drug + 70 days).
Time frame: Up to 10 weeks after last study drug administration (maximum of 86 weeks)
The study was conducted at 320 centers in 27 countries. Overall, 5144 participants were screened between January 2012 and March 2013, 2801 of whom were screen failures. Screen failures were mainly due to exclusion criteria met. In addition 2 participants received study drug but did not undergo randomization. They were excluded from analysis.
| Milestone | Placebo Q2W | Alirocumab 150 mg Q2W |
|---|---|---|
| Started | 788 | 1553 |
| Treated | 788 | 1550 |
| Completed | 595 | 1113 |
| Not completed | 193 | 440 |
| Withdrew: Randomized but not treated | 0 | 3 |
| Withdrew: Adverse event | 48 | 113 |
| Withdrew: Death | 6 | 2 |
| Withdrew: Poor compliance to protocol | 38 | 60 |
| Withdrew: Physician decision | 0 | 4 |
| Withdrew: Participant moved | 5 | 19 |
| Withdrew: Consent withdrawn by participant | 34 | 72 |
| Withdrew: Related to study drug administration | 5 | 14 |
| Withdrew: Last visit outside protocol visit window | 51 | 143 |
| Withdrew: Selection criteria finally not met | 0 | 1 |
| Withdrew: Site closure | 0 | 3 |
| Withdrew: Potential lost to follow-up | 3 | 0 |
| Withdrew: Other | 3 | 6 |
Reported adverse events are treatment-emergent adverse events that is AEs that developed/worsened during the 'treatment-emergent period' (the time from the first dose of study drug up to the last dose of study drug +70 days).
| percentage of participants | Placebo Q2W | Alirocumab 150 mg Q2W |
|---|---|---|
| Any AE | 82.5 | 81.0 |
| Any Serious AE | 19.5 | 18.7 |
| Any AE leading to death | 1.3 | 0.5 |
| Any AE leading to treatment discontinuation | 5.8 | 7.2 |
Adjusted least-squares (LS) means and standard errors at Week 24 were obtained from a mixed-effect model with repeated measures (MMRM) to account for missing data. All available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment were used in the model (ITT analysis).
| percent change | Placebo Q2W | Alirocumab 150 mg Q2W |
|---|---|---|
| Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-Treat (ITT) Analysis | 0.8 ± 1.0 | -61.0 ± 0.7 |
Adjusted LS means and standard errors at Week 24 were obtained from MMRM model including available post-baseline on-treatment data from Week 4 to Week 52 (i.e. up to 21 days after last injection) (on-treatment analysis).
| percent change | Placebo Q2W | Alirocumab 150 mg Q2W |
|---|---|---|
| Percent Change From Baseline in Calculated LDL-C at Week 24 - On-Treatment Analysis | 0.7 ± 1.0 | -62.8 ± 0.7 |
Adjusted LS means and standard errors at Week 12 from MMRM model including available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.
| percent change | Placebo Q2W | Alirocumab 150 mg Q2W |
|---|---|---|
| Percent Change From Baseline in Calculated LDL-C at Week 12 - ITT Analysis | 1.5 ± 1.0 | -63.3 ± 0.7 |
Adjusted LS means and standard errors at Week 12 from MMRM model including available post-baseline on-treatment data from Week 4 to Week 52 (i.e. up to 21 days after last injection).
| percent change | Placebo Q2W | Alirocumab 150 mg Q2W |
|---|---|---|
| Percent Change From Baseline in Calculated LDL-C at Week 12 - On-treatment Analysis | 1.4 ± 1.0 | -64.2 ± 0.7 |
Measured LDL-C values via beta quantification method. Adjusted LS means and standard errors at Week 24 from MMRM model including available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.
| percent change | Placebo Q2W | Alirocumab 150 mg Q2W |
|---|---|---|
| Percent Change From Baseline in Measured LDL-C at Week 24 - ITT Analysis | 3.5 ± 1.1 | -57.8 ± 0.8 |
Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.
| percent change | Placebo Q2W | Alirocumab 150 mg Q2W |
|---|---|---|
| Percent Change From Baseline in Apolipoprotein (Apo) B at Week 24 - ITT Analysis | 1.2 ± 1.0 | -52.8 ± 0.7 |
Adjusted LS means and standard errors at Week 24 were obtained from MMRM model including available post-baseline on-treatment data from Week 4 to Week 52 (i.e. up to 21 days after last injection).
| percent change | Placebo Q2W | Alirocumab 150 mg Q2W |
|---|---|---|
| Percent Change From Baseline in Apo B at Week 24 - On-Treatment Analysis | 1.2 ± 0.9 | -54.3 ± 0.7 |
Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.
| percent change | Placebo Q2W | Alirocumab 150 mg Q2W |
|---|---|---|
| Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 24 - ITT Analysis | 0.7 ± 0.9 | -51.6 ± 0.6 |
Adjusted LS means and standard errors at Week 24 from MMRM model including available post-baseline on-treatment data from Week 4 to Week 52 (i.e. up to 21 days after last injection).
| percent change | Placebo Q2W | Alirocumab 150 mg Q2W |
|---|---|---|
| Percent Change From Baseline in Non-HDL-C at Week 24 - On-Treatment Analysis | 0.6 ± 0.9 | -53.1 ± 0.6 |
Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.
| percent change | Placebo Q2W | Alirocumab 150 mg Q2W |
|---|---|---|
| Percent Change From Baseline in Total Cholesterol (Total-C) at Week 24 - ITT Analysis | -0.3 ± 0.7 | -37.8 ± 0.5 |
Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.
| percent change | Placebo Q2W | Alirocumab 150 mg Q2W |
|---|---|---|
| Percent Change From Baseline in Apo B at Week 12 - ITT Analysis | 0.5 ± 0.9 | -55.5 ± 0.7 |
Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.
| percent change | Placebo Q2W | Alirocumab 150 mg Q2W |
|---|---|---|
| Percent Change From Baseline in Non-HDL-C at Week 12 - ITT Analysis | 0.9 ± 0.8 | -53.7 ± 0.6 |
Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.
| percent change | Placebo Q2W | Alirocumab 150 mg Q2W |
|---|---|---|
| Percent Change From Baseline in Total-C at Week 12 - ITT Analysis | 0.2 ± 0.6 | -38.8 ± 0.4 |
Very high CV risk: Heterozygous Familial Hypercholesterolemia (heFH) participants with coronary heart disease (CHD) or CHD risk equivalents or non- Familial Hypercholesterolemia (FH). High CV risk: heFH participants without CHD or CHD risk equivalents. CHD risk equivalent: peripheral arterial disease, ischemic stroke, moderate chronic kidney disease (estimated glomerular filtration rate, 30 to \<60 ml/minute/1.73 m\^2 of body-surface area), or diabetes mellitus plus 2 or more additional risk factors (hypertension; ankle-brachial index of ≤0.90; microalbuminuria, macroalbuminuria, or a urinary dipstick result of \>2+ protein; preproliferative or proliferative retinopathy or laser treatment for retinopathy; or family history of premature CHD). Adjusted percentages at Week 24 were obtained from multiple imputation approach model for handling of missing data. All available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment were included in imputation model.
| percentage of participants | Placebo Q2W | Alirocumab 150 mg Q2W |
|---|---|---|
| Percentage of Very High Cardiovascular (CV) Risk Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) or High CV Risk Participants Reaching Calculated LDL-C <100 mg/dL (2.59 mmol/L) at Week 24 - ITT Analysis | 8.5 | 80.7 |
Adjusted percentages at Week 24 were from multiple imputation approach model including available post-baseline on-treatment data from Week 4 to Week 52 (i.e. up to 21 days after last injection).
| percentage of participants | Placebo Q2W | Alirocumab 150 mg Q2W |
|---|---|---|
| Percentage of Very High CV Risk Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) or High CV Risk Participants Reaching Calculated LDL-C <100 mg/dL (2.59 mmol/L) at Week 24 - On-Treatment Analysis | 8.5 | 82.8 |
Adjusted percentages at Week 24 were obtained from multiple imputation approach model for handling of missing data. All available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment were included in the imputation model.
| percentage of participants | Placebo Q2W | Alirocumab 150 mg Q2W |
|---|---|---|
| Percentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - ITT Analysis | 8.0 | 79.3 |
Adjusted percentages at Week 24 from multiple imputation approach model including available post-baseline data from Week 4 to Week 52 (i.e. up to 21 days after last injection).
| percentage of participants | Placebo Q2W | Alirocumab 150 mg Q2W |
|---|---|---|
| Percentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - On-Treatment Analysis | 8.0 | 81.2 |
Adjusted means and standard errors at Week 24 were obtained from multiple imputation approach followed by robust regression model for handling of missing data. All available post-baseline data from Week 4 to Week 52 regardless of status on-or off-treatment were included in the imputation model.
| percent change | Placebo Q2W | Alirocumab 150 mg Q2W |
|---|---|---|
| Percent Change From Baseline in Lipoprotein (a) at Week 24 - ITT Analysis | -3.7 ± 1.0 | -29.3 ± 0.7 |
Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.
| percent change | Placebo Q2W | Alirocumab 150 mg Q2W |
|---|---|---|
| Percent Change From Baseline in HDL-C at Week 24 - ITT Analysis | -0.6 ± 0.5 | 4.0 ± 0.4 |
Adjusted means and standard errors at Week 24 from multiple imputation approach followed by robust regression model including all available post-baseline data from Week 4 to Week 52 regardless of status on-or off-treatment.
| percent change | Placebo Q2W | Alirocumab 150 mg Q2W |
|---|---|---|
| Percent Change From Baseline in Fasting Triglycerides at Week 24 - ITT Analysis | 1.8 ± 1.2 | -15.6 ± 0.8 |
Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.
| percent change | Placebo Q2W | Alirocumab 150 mg Q2W |
|---|---|---|
| Percent Change From Baseline in Apo A1 at Week 24 - ITT Analysis | 1.2 ± 0.6 | 4.0 ± 0.4 |
Adjusted means and standard errors at Week 12 from multiple imputation approach followed by robust regression model including all available post-baseline data from Week 4 to Week 52 regardless of status on-or off-treatment.
| percent change | Placebo Q2W | Alirocumab 150 mg Q2W |
|---|---|---|
| Percent Change From Baseline in Lipoprotein (a) at Week 12 - ITT Analysis | -3.1 ± 1.0 | -28.2 ± 0.7 |
Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.
| percent change | Placebo Q2W | Alirocumab 150 mg Q2W |
|---|---|---|
| Percent Change From Baseline in HDL-C at Week 12 - ITT Analysis | 0.2 ± 0.5 | 5.8 ± 0.4 |
Adjusted means and standard errors at Week 12 from multiple imputation approach followed by robust regression model including all available post-baseline data from Week 4 to Week 52 regardless of status on-or off-treatment.
| percent change | Placebo Q2W | Alirocumab 150 mg Q2W |
|---|---|---|
| Percent Change From Baseline in Fasting Triglycerides at Week 12 - ITT Analysis | 1.2 ± 1.1 | -16.7 ± 0.8 |
Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.
| percent change | Placebo Q2W | Alirocumab 150 mg Q2W |
|---|---|---|
| Percent Change From Baseline in Apo A1 at Week 12 - ITT Analysis | 0.6 ± 0.5 | 4.6 ± 0.3 |
Adjusted LS means and standard errors at Week 52 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.
| percent change | Placebo Q2W | Alirocumab 150 mg Q2W |
|---|---|---|
| Percent Change From Baseline in Calculated LDL-C at Week 52 - ITT Analysis | 4.4 ± 1.2 | -56.8 ± 0.8 |
Adjusted LS means and standard errors at Week 52 from MMRM model including available post-baseline on-treatment data from Week 4 to Week 52 (i.e. up to 21 days after last injection).
| percent change | Placebo Q2W | Alirocumab 150 mg Q2W |
|---|---|---|
| Percent Change From Baseline in Calculated LDL-C at Week 52 - On-Treatment Analysis | 4.6 ± 1.1 | -59.9 ± 0.8 |
Adjusted LS means and standard errors at Week 78 from MMRM model including all available post-baseline data from Week 4 to Week 78 regardless of status on- or off-treatment.
| percent change | Placebo Q2W | Alirocumab 150 mg Q2W |
|---|---|---|
| Percent Change From Baseline in Calculated LDL-C at Week 78 - ITT Analysis | 3.6 ± 1.3 | -52.4 ± 0.9 |
Adjusted LS means and standard errors at Week 78 from MMRM model including available post-baseline on-treatment data from Week 4 to Week 78 (i.e. up to 21 days after last injection).
| percent change | Placebo Q2W | Alirocumab 150 mg Q2W |
|---|---|---|
| Percent Change From Baseline in Calculated LDL-C at Week 78 - On-Treatment Analysis | 3.9 ± 1.2 | -58.0 ± 0.9 |
CV events included coronary heart disease (CHD) death; non-fatal myocardial infarction (MI); fatal and non-fatal ischemic stroke; unstable angina requiring hospitalization; congestive heart failure (CHF) requiring hospitalization; ischemia-driven coronary revascularization procedure. Reported events are CV events as confirmed by an independent Clinical Events Committee (CEC) that occurred during the treatment emergent period ( i.e. from first dose up to the last dose of study drug + 70 days).
| percentage of participants | Placebo Q2W | Alirocumab 150 mg Q2W |
|---|---|---|
| Percentage of Participants Who Experienced Cardiovascular (CV) Events | 5.1 | 4.6 |
Major adverse CV events were defined as all adverse CV events except Congestive heart failure (CHF) requiring hospitalization; and ischemia-driven coronary revascularization procedure.
| percentage of participants | Placebo Q2W | Alirocumab 150 mg Q2W |
|---|---|---|
| Percentage of Participants Who Experienced Major Adverse CV Events | 3.3 | 1.7 |
Collected over All Adverse Events (AE) were collected from signature of the informed consent form up to the final visit (Week 86 post-treatment follow-up visit) regardless of seriousness or relationship to investigational product.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo Q2W | — | 154/788 (19.5%) | 366/788 (46.4%) |
| Alirocumab 150 mg Q2W | — | 290/1,550 (18.7%) | 707/1,550 (45.6%) |
| Event | Placebo Q2W | Alirocumab 150 mg Q2W |
|---|---|---|
| Angina unstableCardiac disorders | 9/788 | 29/1550 |
| Acute myocardial infarctionCardiac disorders | 11/788 | 9/1550 |
| PneumoniaInfections and infestations | 7/788 | 6/1550 |
| Atrial fibrillationCardiac disorders | 7/788 | 9/1550 |
| Non-cardiac chest painGeneral disorders | 2/788 | 13/1550 |
| SyncopeNervous system disorders | 6/788 | 11/1550 |
| Angina pectorisCardiac disorders | 6/788 | 9/1550 |
| Acute coronary syndromeCardiac disorders | 6/788 | 2/1550 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 6/788 | 4/1550 |
| Coronary artery diseaseCardiac disorders | 3/788 | 10/1550 |
| Event | Placebo Q2W | Alirocumab 150 mg Q2W |
|---|---|---|
| NasopharyngitisInfections and infestations | 103/788 | 209/1550 |
| Upper respiratory tract infectionInfections and infestations | 68/788 | 114/1550 |
| Urinary tract infectionInfections and infestations | 54/788 | 87/1550 |
| Back painMusculoskeletal and connective tissue disorders | 52/788 | 84/1550 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 52/788 | 80/1550 |
| Injection site reactionGeneral disorders | 33/788 | 91/1550 |
| DiarrhoeaGastrointestinal disorders | 45/788 | 89/1550 |
| InfluenzaInfections and infestations | 43/788 | 88/1550 |
| HeadacheNervous system disorders | 44/788 | 76/1550 |
| MyalgiaMusculoskeletal and connective tissue disorders | 23/788 | 84/1550 |
| Age, Continuous(years) | Placebo Q2W | Alirocumab 150 mg Q2W | Total |
|---|---|---|---|
| Mean | 60.6 ± 10.4 | 60.4 ± 10.4 | 60.5 ± 10.4 |
| Sex: Female, Male(Participants) | Placebo Q2W | Alirocumab 150 mg Q2W | Total |
|---|---|---|---|
| Female | 314 | 570 | 884 |
| Male | 474 | 983 | 1457 |
| Calculated LDL-C in mg/dL(mg/dL) | Placebo Q2W | Alirocumab 150 mg Q2W | Total |
|---|---|---|---|
| Mean | 121.9 ± 41.4 | 122.7 ± 42.6 | 122.4 ± 42.2 |
| Calculated LDL-C in mmol/L(mmol/L) | Placebo Q2W | Alirocumab 150 mg Q2W | Total |
|---|---|---|---|
| Mean | 3.157 ± 1.073 | 3.178 ± 1.102 | 3.171 ± 1.092 |
Showing the first 100 of 320 sites across 27 countries. Choose a country and city above to see the rest.
The record gives a start of Jan 2012, a primary completion of Nov 2014 and a completion of Nov 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2015, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Alirocumab